Skip to content
GRAPHORA
Menu
My Maya

AI companionship & healthcare

What if useful context stayed with the conversation?

A new member opportunity in personal-context AI.

GRAPHORA VENTURES · PUBLIC OVERVIEW
My MayaA new member opportunity in personal-context AI.
FocusPersonal-context AI
Initial applicationHealthcare
StatusIn development

The opportunity, in focus.

My Maya is developing an AI companion designed to preserve personal context across healthcare conversations and everyday life. Healthcare is its initial application.

Graphora · Approved public company overview

Building a connected health experience

01

Remember

Preserve useful context across conversations.

02

Connect

Bring relevant information and care journeys together.

03

Validate

Evaluate evidence, safety, and readiness before broader adoption.

An editorial summary of the public positioning—not a product-performance assessment.

Why this belongs in the conversation.

Editorial perspective · Not investment advice

Graphora’s selection perspective is that continuity of context could be useful across complex workflows. Members with relevant healthcare, product and enterprise experience can help evaluate where that approach creates practical value.

Where members could add value.

01

Healthcare experience

Understanding care transitions and the needs of patients and care teams.

02

Product development

Experience building reliable, usable AI products.

03

Commercial relationships

Relevant introductions for potential pilots and distribution.

What still deserves diligence

This is a development-stage proposition. Clinical benefits, adoption and commercial viability require evidence; a public description is not validation of product performance.

Explore the member opportunity.

Confidential documents, financing proposals and member participation remain in the protected opportunity page. Access, terms, eligibility, confidentiality, and application availability are checked in the protected member experience.

Review opportunity

Public sources reviewed 2026-10-13. This is Graphora’s editorial perspective, not an investment recommendation or an account of an investment committee decision. Company descriptions are attributed statements, not independently verified findings. Imagery is credited to its public source; all marks and images belong to their respective owners.

For information only. Not investment, legal, tax, or medical advice; not an offer, solicitation, recommendation, approval, or guarantee. Private investments may be illiquid and may result in total loss. Listing on Graphora does not establish suitability for any individual.

Public editorial reviewed . Company overview and sources ↗